Iron deficiency anemia in chronic kidney disease: Uncertainties and cautions

Hemodialysis International

Volumn 21, Issue , 2017, Pages S78-S82

  Agarwal, Rajiv ^a  

^a RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Chronic kidney disease; efficacy; iron deficiency anemia; randomized trials; safety issues

Indexed keywords

IRON; HEMOGLOBIN;

ABDOMINAL DISCOMFORT; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL ASSESSMENT; CONSTIPATION; DRUG EFFICACY; DRUG SAFETY; ESTIMATED GLOMERULAR FILTRATION RATE; HUMAN; IRON DEFICIENCY ANEMIA; IRON THERAPY; REVIEW; STAPHYLOCOCCUS EPIDERMIDIS; COMPLICATION; FEMALE; HEMODIALYSIS; MALE;

ANEMIA, IRON-DEFICIENCY; FEMALE; HEMOGLOBINS; HUMANS; IRON; MALE; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 85017548246     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/hdi.12561     Document Type: Review

References (23)

1. Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: Results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol. 2002; 13:504–510.
2. El-Achkar TM, Ohmit SE, McCullough PA, et al. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. Kidney Int. 2005; 67:1483–1488.
3. Elliott J, Mishler D, Agarwal R. Hyporesponsiveness to erythropoietin: Causes and management. Adv Chronic Kidney Dis. 2009; 16:94–100.
4. Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextrans [see comments]. Am J Kidney Dis. 1999; 33:464–470.
5. Lu M, Cohen MH, Rieves D, Pazdur R. FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol. 2010; 85:315–319.
6. Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int. 2015; 88:905–914.
7. Rozen-Zvi B, Gafter-Gvili A, Paul M, et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: Systematic review and meta-analysis. Am J Kidney Dis. 2008; 52:897–906.
8. Stoves J, Inglis H, Newstead CG. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant. 2001; 16:967–974.
9. Kidney Disease Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012; 2:279–335.
10. Macdougall IC, Bock AH, Carrera F, et al. FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant. 2014; 29:2075–2084.:
11. Parkkinen J, von Bonsdorff L, Peltonen S, et al. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant. 2000; 15:1827–1834.:
12. Zager RA, Johnson AC, Hanson SY. Parenteral iron therapy exacerbates experimental sepsis. Rapid communication. Kidney Int. 2004; 65:2108–2112.
13. Zager RA, Johnson AC, Hanson SY, Lund S. Parenteral iron compounds sensitize mice to injury-initiated TNF-alpha mRNA production and TNF-alpha release. Am J Physiol Renal Physiol. 2005; 288:F290–F297.
14. Sengoelge G, Kletzmayr J, Ferrara I, et al. Impairment of transendothelial leukocyte migration by iron complexes. J Am Soc Nephrol. 2003; 14:2639–2644.
15. Sazawal S, Black RE, Ramsan M, et al. Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: Community-based, randomised, placebo-controlled trial. Lancet. 2006; 367:133–143.
16. Drueke T, Witko-Sarsat V, Massy Z, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation. 2002; 106:2212–2217.
17. Becker BN, Himmelfarb J, Henrich WL, Hakim RM. Reassessing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol. 1997; 8:475–486.
18. Agarwal R, Warnock D. Issues related to iron replacement in chronic kidney disease. Semin Nephrol. 2002; 22:479–487.
19. Zager RA, Johnson AC, Hanson SY, Wasse H. Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis. 2002; 40:90–103.
20. Shah SV. Role of iron in progressive renal disease. Am J Kidney Dis. 2001; 37:S30–S33.
21. Zheng H, Huang X, Zhang Q, Katz SD. Iron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects. Kidney Int. 2006; 69:679–684.
22. Agarwal R, Leehey DJ, Olsen SM, Dahl NV. Proteinuria induced by parenteral iron in chronic kidney disease–A comparative randomized controlled trial. Clin J Am Soc Nephrol. 2011; 6:114–121.
23. Rogers SD, Gaillard C, Bock A, et al. Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: An analysis of the 1-year FIND-CKD trial. Nephrol Dial Transplant. 2017; https://doi.org/10.1093/ndt/gfw264